Apex Capital Management’s Edwards Lifesciences EW Stock Holding History

Apex Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$5.41M	Sell	184,050 -27,348	-13%	-$755K	0.12%	148
2015 Q4	$5.57M	Sell	211,398 -2,244	-1%	-$58.3K	0.12%	145
2015 Q3	$5.06M	Buy	213,642 +84	+0%	+$2.03K	0.11%	146
2015 Q2	$5.07M	Sell	213,558 -1,398	-0.7%	-$31.5K	0.11%	148
2015 Q1	$5.1M	Sell	214,956 -19,548	-8%	-$439K	0.12%	148
2014 Q4	$4.98M	Sell	234,504 -2,040	-0.9%	-$41K	0.13%	137
2014 Q3	$4.03M	Buy	+236,544	New	+$3.73M	0.12%	134

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Apex Capital Management's EW Position: Q1 2016 in Review

Apex Capital Management reduced its Edwards Lifesciences (EW) stake by 13% in Q1 2016, selling an estimated $755K and leaving 184,050 shares worth $5.41M. The position accounts for 0.12% of the portfolio, ranked #148.

Apex Capital Management first reported a position in EW in Q3 2014 and has held it in 7 quarters since. The position peaked at $5.57M in Q4 2015. 658 funds tracked by Wall St. Rank hold EW as of Q1 2016.

Apex Capital Management held 184,050 shares of Edwards Lifesciences worth $5.41M as of Q1 2016.
Apex Capital Management sold 27,348 Edwards Lifesciences shares in Q1 2016, an estimated $755K.
Edwards Lifesciences made up 0.12% of Apex Capital Management's portfolio in Q1 2016, its #148 holding.
Apex Capital Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 7 quarters since.
Apex Capital Management's Edwards Lifesciences position peaked at $5.57M in Q4 2015.
658 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.